June is recognized as Post-Traumatic Stress Disorder (PTSD) Awareness Month, a time to raise awareness of a complex condition that impacts millions of people worldwide.

Approximately 6% of the U.S. population will have PTSD at some point in their lives (National Center for PTSD). PTSD is a mental health condition triggered by experiencing or witnessing a traumatic event. It can affect anyone who has faced severe stress or trauma and it may have a significant impact on a person’s daily life, relationships, and overall well-being.

MMRI researchers are aiming to identify the genetic and epigenetic causes of neurocognitive ailments like PTSD, with the hopes of developing cutting-edge treatments and cures. Currently, our team is working to identify causal factors associated with the development of post-traumatic stress disorder (PTSD).

MMRI principal investigator, Dr. Kessinger aims to develop molecular imaging targets of novel biomarkers of PTSD. His goal is to use these imaging targets to aid the in detection and treatment of PTSD and its symptoms. His current projects on PTSD involve the role of inflammation within the brain post trauma, specifically looking at microglia’s role within this process.

To learn more about our ongoing research initiatives or support our mission, please visit mmri.edu.

PLATINUM INVESTORS